AB-2100 is under clinical development by Arsenal Biosciences and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Metastatic Renal Cell Carcinoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AB-2100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AB-2100 overview

AB-2100 is under development for the treatment of metastatic clear cell renal cell carcinoma. The drug candidate comprises of T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing prostate specific membrane antigen (PSMA) and cells expressing carbonic anhydrase IX (CAIX). It is being developed based on PrimeR logic gate technology. It is administered through intravenous route.

Arsenal Biosciences overview

Arsenal Biosciences is a cell therapy company that discovers, develops and commercializes immune cell therapies to treat cancer. It utilizes its synthetic biology compositions made up of PrimeR logic gates, CARchitecture acquired gene expression controls, and CellFoundry mediated nonviral manufacturing to develop cell therapy product candidates. Arsenal Biosciences was funded by Kleiner Perkins, Westlake Village Biopartners, Euclidean Capital, Osage University Partners and UCSF foundation investment company. The company works in collaboration with Bristol Myers Squibb Co to evaluate T cell therapies for the treatment of solid tumors. Arsenal Biosciences is headquartered in South San Francisco, California, the US.

For a complete picture of AB-2100’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.